Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction

Experimental Cell Research

Volumn 250, Issue 1, 1999, Pages 231-240

  Yebra, Mayra ^a   Goretzki, Lothar ^a   Pfeifer, Michelle ^a   Mueller, Barbara M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cell migration; UPA; UPAR; 1 integrin

Indexed keywords

FIBRONECTIN; INTEGRIN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL MIGRATION; CELL MOTILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

EID: 0033542781     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4510     Document Type: Article

References (45)

1. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:1993;161-195.
2. Andreasen P. A., Kjoller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer. 72:1997;1-22.
3. Chapman H. A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:1997;714-724.
4. Dear A. E., Metcalf R. L. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur. J. Biochem. 252:1998;185-193.
5. Crowley C. W., Cohen R. L., Lucas B. K., Liu G., Shuman M. A., Levinson A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:1993;5021-5025.
6. Achbarou A., Kaiser S., Tremblay G., Ste-Marie L.-G., Brodt P., Goltzman D., Rabbani S. A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:1994;2372-2377.
7. Rabbani S. A., Harakidas P., Davidson D. J., Henkin J., Mazar A. P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminigen activator (uPA). Int. J. Cancer. 63:1995;840-845.
8. Soff G. A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H. C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96:1995;2593-2600.
9. Rao N. K., Shi G.-P., Chapman H. A. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest. 96:1995;465-474.
10. Busso N., Masur S. K., Lazega D., Waxman S., Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanisms for signal transduction in human epithelial cells. J. Cell Biol. 126:1994;259-270.
11. 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1995;1381-1390.
12. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15:1996;1572-1582.
13. Koshelnick Y., Ehart M., Hufnagl P., Heinrich P. C., Binder B. R. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272:1997;28563-28567.
14. Dumler I., Weis A., Mayborodda O. A., Masch C., Jerke U., Haller H., Gulba D. C. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273:1998;315-321.
15. Stahl A., Mueller B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:1994;3066-3071.
16. Hoosein N. M., Boyd D. D., Hollas W. J., Mazar A., Henkin J., Chung L. W. K. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 3:1991;255-264.
17. Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V., Chapman H. A. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
18. Hanks S. K., Polte T. R. Signaling through focal adhesion kinase. BioEssays. 19:1997;137-145.
19. Schwartz M. A., Schaller M. D., Ginsberg M. H. Integrins: Emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11:1995;549-599.
20. Quax P. H. A., Boxman I. L. A., Van Kesteren C. A. M., Verheijen J. H., Ponec M. Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis. 8:1994;221-228.
21. Lu H., Mabilat C., Yeh P., Guitton J.-D., Li H., Pouchelet M., Shoevaert D., Legrand Y., Soria J., Soria C. Blockage of urokinase receptors reduces in vitro the motility and deformability of endothelial cells. FEBS Lett. 380:1996;21-24.
22. Yebra M., Parry G. C. N., Strömblad S., Mackman N., Rosenberg S., Mueller B. M., Cheresh D. A. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J. Biol. Chem. 271:1996;29393-29399.
23. Del Rosso M., Anichini E., Pedersen N., Blasi F., Fibbi G., Pucci M., Ruggiero M. Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epithelial cells. Biochem. Biophys. Res. Commun. 190:1993;347-352.
24. Tang H., Kerins D. M., Hao Q., Inagami T., Vaughan D. E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273:1998;18268-18272.
25. Guan J. L. Role of focal adhesion kinase in integrin signaling. Int. J. Biochem. Cell Biol. 29:1997;1085-1096.
26. Ilic D., Furuta Y., Kanazawa S., Takeda N., Sobue K., Nakatsuji N., Nomura S., Fujimoto J., Okada M., Yamamoto T., Aizawa S. Reduced cell motility and enhanced focal contact formation in cells from FAK deficient mice. Nature. 377:1995;539-544.
27. Romer L. H., McLean N., Turner C. E., Burridge K. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells. Mol. Biol. Cell. 5:1994;349-361.
28. Gates R. E., King L. E. Jr., Hanks S. K., Nanney L. B. Potential role for focal adhesion kinase in migrating and proliferating keratinocytes near epidermal wounds in culture. Cell Growth Differ. 5:1994;891-899.
29. Cary L. A., Chang J. F., Guan J.-L. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell Sci. 109:1996;1787-1794.
30. CSK in human metastatic prostate carcinoma. Int. J. Cancer. 68:1996;164-171.
31. Weiner T. M., Liu E. T., Craven R. J., Cance W. G. Expression of focal adhesion kinase gene and invasive cancer. Lancet. 342:1993;1024-1025.
32. Owens L. V., Xu L., Craven R. J., Dent G. A., Weiner T. M., Kornberg L., Liu E. T. Overexpression of the focal adhesion kinase (p125 FAK) in invasive human tumors. Cancer Res. 55:1995;2752-2755.
33. Cas, a Src homology 3-containing molecule having multiple Src homology 2-binding motifs. J. Biol. Chem. 270:1995;15398-15402.
34. Sakai R., Iwamatsu A., Hirano N., Ogawa S., Tanaka T., Mano H., Yazaki Y., Hirai H. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation dependent manner. EMBO J. 13:1994;3748-3756.
35. Vuori K., Hirai H., Aizawa S., Ruoslahti E. Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: A role for Src family kinases. Mol. Cell. Biol. 16:1996;2606-2613.
36. Cas. Nature Genet. 19:1998;361-365.
37. Cas as a mediator of focal adhesion kinase-promoted cell migration. J. Cell Biol. 140:1998;211-221.
38. Klemke R. L., Leng J., Molander R., Brooks P. C., Vuori K., Cheresh D. A. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J. Cell Biol. 140:1997;961-972.
39. Reinartz J., Schafer B., Batrla R., Klein C. E., Kramer M. D. Plasmin abrogates αvβ5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp. Cell Res. 220:1995;274-282.
40. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., Chapman H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380-32388.
41. Xue W., Mizukami I., Todd R. F. III, Petty H. R. Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57:1997;1682-1689.
42. Kindzelskii A. L., Laska Z. O., Todd R. F. III, Petty H. R. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (αMβ2, CD11b/CD18) during neutrophil polarization. J. Immunol. 156:1996;297-309.
43. Kindzelskii A. L., Eszes M. M., Todd R. F. III, Petty H. R. Proximity oscillations of complement type 4 (αxβ2) and urokinase receptors on migrating neutrophils. Biophys. J. 73:1997;1777-1784.
44. May A. E., Kanse S. M., Lund L. R., Gisler R. H., Imhof B. A., Preissner K. T. Urokinase receptor (CD87) regulates leukocyte recruitment via β2 integrins in vivo. J. Exp. Med. 188:1998;1029-1037.
45. Petty H. R., Todd R. F. Integrins as promiscuous signal transduction devices III. Immunol. Today. 17:1996;209-212.